


EGC

Distal


Laparoskopi

KLASS01

2006-2010  
Non-inferiority  
5y-OS




A Overall survival



No. at risk

|              |     |     |     |     |     |     |     |     |     |     |     |   |
|--------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|
| Laparoscopy  | 673 | 667 | 659 | 650 | 640 | 629 | 618 | 551 | 384 | 280 | 156 | 9 |
| Open surgery | 686 | 675 | 668 | 658 | 651 | 631 | 618 | 546 | 375 | 268 | 153 | 9 |

B Cancer-specific survival



No. at risk

|              |     |     |     |     |     |     |     |     |     |     |     |   |
|--------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|
| Laparoscopy  | 673 | 667 | 659 | 650 | 640 | 629 | 618 | 551 | 384 | 280 | 156 | 9 |
| Open surgery | 686 | 675 | 668 | 658 | 651 | 631 | 618 | 546 | 375 | 268 | 153 | 9 |

5y-OS

94.2% LDG grup

93.3% ODG grup

**similar overall and cancer-specific survival** rates between patients receiving laparoscopic and open distal gastrectomy




# EGC

# Distal

# Laparoskopi

## JCOG0912

2010-2013  
Non-inferiority  
relapse-free survival



5y-RFS

95.1% LDG grup

94% ODG grup

**non-inferiority of LADG** compared with ODG for clinical stage I gastric cancer relapse-free survival, suggesting that LADG should be considered a standard treatment option when performed by experienced surgeons.